| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE)
CERE Technical Analysis
4
| As on 9th Jun 2023 CERE STOCK Price closed @ 32.83 and we RECOMMEND Buy for LONG-TERM with Stoploss of 29.10 & Strong Buy for SHORT-TERM with Stoploss of 28.83 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CERESTOCK Price
| Open | 33.87 | Change | Price | % |
| High | 33.99 | 1 Day | -0.84 | -2.49 |
| Low | 32.58 | 1 Week | 0.23 | 0.71 |
| Close | 32.83 | 1 Month | 4.46 | 15.72 |
| Volume | 347055 | 1 Year | -0.57 | -1.71 |
| 52 Week High 41.42 | 52 Week Low 20.62 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CERE Daily Charts |
CERE Intraday Charts |
Whats New @ Bazaartrend |
CERE Free Analysis |
|
|
CERE Important Levels Intraday
| RESISTANCE | 35.55 |
| RESISTANCE | 34.68 |
| RESISTANCE | 34.14 |
| RESISTANCE | 33.60 |
| SUPPORT | 32.06 |
| SUPPORT | 31.52 |
| SUPPORT | 30.98 |
| SUPPORT | 30.11 |
CERE Forecast May 2024
| 4th UP Forecast | 54.76 |
| 3rd UP Forecast | 47.73 |
| 2nd UP Forecast | 43.38 |
| 1st UP Forecast | 39.03 |
| 1st DOWN Forecast | 26.63 |
| 2nd DOWN Forecast | 22.28 |
| 3rd DOWN Forecast | 17.93 |
| 4th DOWN Forecast | 10.9 |
CERE Weekly Forecast
| 4th UP Forecast | 40.96 |
| 3rd UP Forecast | 38.35 |
| 2nd UP Forecast | 36.74 |
| 1st UP Forecast | 35.13 |
| 1st DOWN Forecast | 30.53 |
| 2nd DOWN Forecast | 28.92 |
| 3rd DOWN Forecast | 27.31 |
| 4th DOWN Forecast | 24.70 |
CERE Forecast2024
| 4th UP Forecast | 74.45 |
| 3rd UP Forecast | 61.1 |
| 2nd UP Forecast | 52.85 |
| 1st UP Forecast | 44.6 |
| 1st DOWN Forecast | 21.06 |
| 2nd DOWN Forecast | 12.81 |
| 3rd DOWN Forecast | 4.56 |
| 4th DOWN Forecast | -8.79 |
Cerevel Therapeutics Holdings Inc ( NASDAQ USA Symbol : CERE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CERE Business Profile
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Address: 222 Jacobs Street, Cambridge, MA, United States, 02141
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service